SGLT2抑制剂恩格列净与安慰剂及DPP-4抑制剂利格列汀与安慰剂在年轻2型糖尿病患者中的疗效与安全性(DINAMO):一项多中心、随机、双盲、平行组、3期试验
该多中心双盲3期试验纳入10-17岁2型糖尿病患者158例,随机分入恩格列净10mg、利格列汀5mg或安慰剂组,主要终点为26周HbA1c自基线变化。恩格列净汇总组较安慰剂显著降低HbA1c(-0.84% vs 安慰剂,95%CI -1.50至-0.19,p=0.012),利格列汀较安慰剂无显著差异(-0.34%,95%CI -0.99至0.30,p=0.29)。
要点
- 恩格列净汇总组26周HbA1c较基线降低-0.84%,安慰剂校正后差异有统计学意义(p=0.012)。
- 利格列汀组26周HbA1c较基线降低-0.34%,与安慰剂比较无显著差异(p=0.29)。
- 不良事件发生率:安慰剂组64%、恩格列净汇总组77%、利格列汀组71%;无严重低血糖报告。
核心结论
- 恩格列净提供了有临床意义的安慰剂校正后HbA1c降低,而利格列汀未能提供,恩格列净可能为年轻2型糖尿病患者提供新的治疗选择。
研究设计与样本
- 多中心、随机、双盲、平行组、3期试验,在15个国家108个中心进行,纳入10-17岁、HbA1c 6.5-10.5%(48-91 mmol/mol)、既往接受二甲双胍或胰岛素治疗的2型糖尿病患者。
- 2018年4月26日至2022年5月26日筛查262例,158例(60%)随机分配:安慰剂53例(34%)、恩格列净10mg 52例(33%)、利格列汀53例(34%)。
- 恩格列净组第12周HbA1c未低于7.0%(<53 mmol/mol)者于第14周二次随机(1:1)维持10mg或增至25mg;安慰剂组第26周盲法重新分配(1:1:1)至利格列汀5mg或恩格列净10mg或25mg。
- 主要终点为26周HbA1c自基线变化,恩格列净结果基于所有恩格列净使用者的汇总分析;安全性评估至52周。
主要发现
- 26周HbA1c自基线校正平均变化:恩格列净汇总组-0.84%(-9.2 mmol/mol)vs 安慰剂,差异95%CI -1.50至-0.19(-16.4至-2.1),p=0.012。
- 26周HbA1c自基线校正平均变化:利格列汀组-0.34%(-3.8 mmol/mol)vs 安慰剂,差异95%CI -0.99至0.30(-10.8至3.3),p=0.29。
- 截至26周不良事件:安慰剂组34例(64%)、恩格列净汇总组40例(77%)、利格列汀组37例(71%)。
- 严重不良事件:安慰剂组2例(4%)、恩格列净汇总组1例(2%)、利格列汀组1例(2%)。
- 低血糖是报告最频繁的不良事件,接受活性药物治疗者发生率高于安慰剂;未报告严重低血糖病例。
临床怎么用
- 作者认为恩格列净提供了有临床意义的安慰剂校正后HbA1c降低,可能为年轻2型糖尿病患者提供新的治疗选择,而利格列汀未能提供此降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes. METHODS: In this double-blind, placebo-controlled trial done in 108 centres in 15 countries, participants with type 2 diabetes (aged 10-17 years; HbA1c 6·5-10·5% [48-91 mmol/mol]) who had been previously treated with metformin or insulin were randomly assigned (1:1:1) to oral empagliflozin 10 mg, oral linagliptin 5 mg, or placebo. Participants in the empagliflozin group who did not have HbA1c below 7·0% (<53 mmol/mol) by week 12 underwent a second double-blinded randomisation (1:1) at week 14, either remaining on 10 mg or increasing to 25 mg. Participants in the placebo group were randomly reassigned (1:1:1) in a double-blinded manner at week 26 to linagliptin 5 mg or one of the empagliflozin doses (10 mg or 25 mg). Investigators were masked throughout the trial and received assignments of blinded medication kits through interactive response technology for all participants at the initial randomisation and for the re-randomisations at weeks 14 and 26. The primary outcome was change from baseline in HbA1c at 26 weeks. For empagliflozin, results were based on a pooled analysis for all participants on empagliflozin. Safety was assessed until week 52. This trial is registered with ClinicalTrials.gov, NCT03429543. FINDINGS: Between April 26, 2018, and May 26, 2022, of 262 screened participants, 158 (60%) were randomly assigned to treatment (53 [34%] to placebo, 52 [33%] to empagliflozin 10 mg, and 53 [34%] to linagliptin). For the primary outcome, the adjusted mean HbA1c change from baseline at week 26 was -0·84% [-9·2 mmol/mol] in the empagliflozin pooled group versus placebo (95% CI -1·50 to -0·19 [-16·4 to -2·1]; p=0·012); the corresponding change from baseline for linagliptin versus placebo was -0·34% [-3·8 mmol/mol; 95% CI -0·99 to 0·30 [-10·8 to 3·3]; p=0·29). Adverse events occurred in 34 (64%) participants in the placebo group, 40 (77%) in the empagliflozin pooled group, and 37 (71%) in the linagliptin group, up to week 26. Of these, severe adverse events were reported in two (4%) participants in the placebo group, one (2%) in the empagliflozin pooled group, and one (2%) in the linagliptin group. Hypoglycaemia was the most frequently reported adverse event with higher rates for those on active drug treatment compared with placebo. No severe hypoglycaemia cases were reported. INTERPRETATION: Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes. FUNDING: The Boehringer Ingelheim and Eli Lilly and Company Alliance.
引用
- Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023. PMID: 36738751. doi:10.1016/S2213-8587(22)00387-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。